Market Currents
Celgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound...
-
Wednesday, October 3, 2012, 9:04 AM ETCelgene (CELG) and privately held VentiRx sign a deal to develop the latter's VTX-2337 compound for the treatment of cancer. Under the agreement, Celgene will pay $35M for further R&D, and will retain the option to make an equity investment in VentiRx or aquire the company.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
